Key facts
Explore key financial and product revenue facts about Bristol Myers Squibb.
ELIQUIS® (apixaban), $13.3 billion
OPDIVO®(nivolumab), $9.3 billion
REVLIMID® (lenalidomide), $5.8 billion
ORENCIA® (abatacept), $3.7 billion
POMALYST® / Imnovid® (pomalidomide), $3.5 billion
YERVOY® (ipilimumab), $2.5 billion
REBLOZYL® (luspatercept-aamt), $1.8 billion
SPRYCEL® (dasatinib), $1.3 billion
OPDUALAG™(nivolumab and relatlimab-rmbw): $928 million
ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), $875 million
BREYANZI® (lisocabtagene maraleucel), $747 million
CAMZYOS® (mavacamten), $602 million
ZEPOSIA® (ozanimod), $566 million
ABECMA® (idecabtagene vicleucel), $406 million
SOTYKTU™(deucravacitinib), $246 million
KRAZATI® (adagrasib) $126 million
AUGTYRO™ (repotrectinib), $38 million
COBENFY™ (xanomeline & trospium chloride), $10 million
Other growth products *, $1.6 billion
Other legacy products **, $925 million
*Includes NULOJIX® (belatacept), ONUREG® (azacitidine tablets), INREBIC® (fedratinib), EMPLICITI® (elotuzumab) and royalty revenue
**Includes other mature brands
Please click on the product links to see the Full Prescribing Information for ABECMA®, ABRAXANE®, AUGTYRO™, BREYANZI®, CAMZYOS® COBENFY™, ELIQUIS®, OPDIVO®, OPDUALAG™, ORENCIA®, POMALYST® , REBLOZYL®, REVLIMID® , SOTYKTU™ , SPRYCEL® , YERVOY® and ZEPOSIA® including Boxed WARNINGS for ABECMA®, ABRAXANE®, BREYANZI®, CAMZYOS®, ELIQUIS®, POMALYST®, REVLIMID®, and Boxed WARNINGS for YERVOY® regarding immune-mediated adverse reaction.
Updated May 2025